Your browser is no longer supported. Please, upgrade your browser.
Settings
GRTS Gritstone Oncology, Inc. daily Stock Chart
GRTS [NASD]
Gritstone Oncology, Inc.
Index- P/E- EPS (ttm)-2.25 Insider Own7.27% Shs Outstand34.35M Perf Week-6.26%
Market Cap359.99M Forward P/E- EPS next Y-2.67 Insider Trans- Shs Float33.43M Perf Month-2.15%
Income-64.80M PEG- EPS next Q-0.66 Inst Own57.80% Short Float6.64% Perf Quarter-15.07%
Sales1.20M P/S299.99 EPS this Y-51.40% Inst Trans1.08% Short Ratio9.84 Perf Half Y-52.21%
Book/sh4.57 P/B2.29 EPS next Y-5.40% ROA-48.40% Target Price23.33 Perf Year-
Cash/sh3.85 P/C2.72 EPS next 5Y- ROE-312.10% 52W Range9.57 - 32.90 Perf YTD-32.17%
Dividend- P/FCF- EPS past 5Y- ROI-41.10% 52W High-68.15% Beta-
Dividend %- Quick Ratio9.60 Sales past 5Y- Gross Margin- 52W Low9.51% ATR0.76
Employees127 Current Ratio9.60 Sales Q/Q- Oper. Margin- RSI (14)43.40 Volatility6.04% 6.03%
OptionableNo Debt/Eq0.00 EPS Q/Q-31.40% Profit Margin- Rel Volume0.72 Prev Close9.98
ShortableYes LT Debt/Eq0.00 EarningsMar 27 Payout- Avg Volume225.72K Price10.48
Recom2.00 SMA20-3.57% SMA50-14.27% SMA200-31.74% Volume163,263 Change5.01%
Mar-15-19Initiated Raymond James Outperform
Mar-07-19Initiated H.C. Wainwright Buy $17
Oct-23-18Initiated Goldman Neutral $18
Oct-23-18Initiated BTIG Research Buy $26
May-13-19 09:01AM  Gritstone Oncology Reports First Quarter 2019 Financial Results and Recent Highlights GlobeNewswire
May-09-19 08:56PM  Heres What Hedge Funds Think About Gritstone Oncology, Inc. (GRTS) Insider Monkey
Apr-25-19 11:42AM  Why Gritstone Oncology Stock Is Sinking Today Motley Fool -12.93%
07:58AM  The Daily Biotech Pulse: Adverum Gets New CFO, Flexion's Osteoarthritis Trial, Bristol-Myers Earnings Benzinga
Apr-24-19 08:53PM  Gritstone Oncology Announces Pricing of $74.8 Million Public Offering of Common Stock GlobeNewswire -5.02%
Apr-23-19 08:08AM  The Daily Biotech Pulse: FDA Accepts Alder's Migraine Drug Application, Gritstone Offering, Lilly's Chinese Sale Benzinga -11.00%
Apr-22-19 04:28PM  Gritstone Oncology Announces Proposed Public Offering of Common Stock GlobeNewswire +5.90%
08:00AM  Gritstone Oncology Announces Clinical Acceleration of Off-The-Shelf Personalized Neoantigen Immunotherapy Program (SLATE) Following FDA Feedback GlobeNewswire
Apr-04-19 08:00AM  Gritstone Oncology Announces the Addition of Eugene Zhukovsky, Expert in Bispecific Biotherapeutics Development, to its Scientific Advisory Board GlobeNewswire +5.13%
Apr-03-19 04:00PM  Gritstone Oncology to Present at Needham Healthcare Conference GlobeNewswire
10:02AM  After inking lease with cancer-fighting company, this new East Bay biotech project is full American City Business Journals
Apr-02-19 04:00PM  Gritstone Oncology Presents Data at AACR Demonstrating MHC Class II Neoantigen Prediction with EDGE Significantly Outperforms Current Prediction Methods GlobeNewswire +9.51%
Mar-28-19 04:00PM  Gritstone Oncology Reports Fourth Quarter and Full Year 2018 Financial Results and Recent Highlights GlobeNewswire +5.47%
Mar-25-19 09:19AM  Health Care Digest: Genentech's tumor-agnostic cancer drug, Novartis' East Bay option and more American City Business Journals
Mar-21-19 04:00PM  Gritstone Oncology Announces First Patient Dosed in a Clinical Study Evaluating its Personalized Immunotherapy, GRANITE-001 GlobeNewswire
Mar-11-19 08:00AM  Gritstone Oncology Announces the Appointment of Technology Executive, Mike Forcht, as Senior Vice President of Human Resources to Support Vision for Growth GlobeNewswire
Mar-05-19 04:00PM  Gritstone Oncology to Present at Two Upcoming Investor Conferences in March GlobeNewswire -8.10%
Feb-27-19 06:12PM  Gritstone Oncology Announces Oral Presentation on MHC Class II Antigen Prediction at the AACR Annual Meeting in April 2019 GlobeNewswire
Feb-20-19 04:00PM  Gritstone Oncology to Present at Leerink Partners Annual Global Healthcare Conference GlobeNewswire
Jan-06-19 08:00AM  Gritstone Oncology Announces Updated Presentation Time at the 37th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Jan-03-19 06:16PM  Gritstone Oncology to Present at the 37th Annual J.P. Morgan Healthcare Conference GlobeNewswire
Dec-28-18 10:11AM  2019 biotech preview: Money is pouring into the Bay Area and so is Big Pharma American City Business Journals
Dec-20-18 04:00PM  Gritstone Oncology Announces FDA Fast Track Designation for GRANITE-001 for the Treatment of Colorectal Cancer GlobeNewswire -17.00%
Dec-19-18 04:17PM  TCR2 Therapeutics Announces Oncology Industry Leader and Expert Andrew Allen, M.D., Ph.D. Joins its Board of Directors PR Newswire -9.32%
Dec-17-18 11:00AM  Gritstone Oncology Announces Publication in Nature Biotechnology of Neoantigen Identification Capabilities of its Artificial Intelligence Platform, EDGE GlobeNewswire -7.08%
Dec-15-18 08:03AM  3 Biotechs Gilead Sciences Could Buy in March Motley Fool
Dec-13-18 05:18PM  Targeting 'bubble baby' disease, this gene therapy company is planting a flag in the East Bay American City Business Journals
Dec-10-18 07:00AM  Gritstone Oncology Advances Solid Tumor Bispecific Antibody Program into Lead Optimization Phase; Appoints Vice President of Antibody Therapeutics to Spearhead GlobeNewswire -11.37%
Nov-26-18 02:03PM  Here's how much better insiders have profited from this year's IPO boom American City Business Journals
Nov-14-18 08:00AM  Gritstone Oncology Reports Third Quarter 2018 Financial Results and Recent Business Highlights GlobeNewswire
Oct-01-18 01:34PM  24 Bay Area companies have gone public so far this year. Here's how they've done. American City Business Journals -5.55%
Sep-28-18 09:18AM  Gritstone Oncology expects to begin trading today, prices at $15 per share MarketWatch
07:24AM  [$$] Gritstone Oncology Prices Upsized IPO at Top of Range The Wall Street Journal
Sep-27-18 09:30PM  Gritstone Oncology Announces Pricing of Initial Public Offering GlobeNewswire
Sep-22-18 04:15PM  The IPO Outlook For The Week: Smart Appliances, A Language App and Drugmakers Benzinga
Gritstone Oncology Inc., an immuno-oncology company, engages in developing tumor-specific cancer immunotherapies to fight various cancer types. Its lead product candidate is GRANITE-001, which is in Phase I/II clinical trial for the treatment of solid tumors, including metastatic non-small cell lung cancer, as well as gastroesophageal, bladder and microsatellite stable, and colorectal cancers. Gritstone Oncology Inc. has a strategic collaboration with bluebird bio, Inc. The company was founded in 2015 and is headquartered in Emeryville, California.